CAMBRIDGE, Mass.—June 27, 2011 — FORMA Therapeutics announced today that it entered into an agreement granting Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), exclusive worldwide rights to acquire a pre-clinical small molecule program against a single undisclosed cancer target.
Related Posts
Exaforce raises $125M Series B to expand AI-native security operations platform
- 13 05 2026
- |
Iterative Health Closes $77 Million Series C to Accelerate the Future of Clinical Research
- 30 04 2026
- |
VAST Data Valued at $30 Billion as AI Drives a New Infrastructure Stack
- 22 04 2026
- |
Southeast Asian startups total funding surges 110 percent year on year to $2.8B in Q1 – Tracxn
- 15 04 2026
- |
Addepar Expands in Singapore as APAC Demands Reshape Data and AI Workflows
- 15 04 2026
- |
